 |
From right: Choi In-hyuk, CEO of Tech Business at Naver, and Kwon-ho Jung, CEO of J&P Medi, pose for a commemorative photo after signing a business agreement at Naver’s 1784 headquarters. (Photo courtesy of Naver) |
[Alpha Biz= Kim Jisun] Naver announced on August 13 that it has signed a comprehensive business agreement with J&P Medi to strengthen the domestic healthcare ecosystem and pursue global market opportunities through AI-powered innovation. The signing ceremony, held at Naver’s 1784 headquarters, was attended by Naver Tech Business CEO Choi In-hyuk and J&P Medi CEO Kwon-ho Jung, along with other executives from both companies.
Under the agreement, Naver will invest in J&P Medi, a leading Korean digital healthcare company specializing in clinical trial data platforms for the pharmaceutical, biotechnology, and medical device sectors. J&P Medi offers a full range of CRO (contract research organization) services, investment support, licensing consulting, and strategic advisory for technology transfers. Its proprietary platform manages and operates clinical data in compliance with international standards, supporting functions such as clinical trials, quality control, and regulatory compliance.
Naver plans to integrate its AI capabilities with J&P Medi’s clinical trial platform to enhance performance and enable digital clinical trial capabilities essential for global expansion. The collaboration will also focus on securing national strategic assets in clinical trial data management, achieving technological self-reliance, and building a digital transformation infrastructure across Korea’s healthcare sector.
Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)
